Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B

Clinical and Vaccine Immunology

Volumn 18, Issue 7, 2011, Pages 1046-1051

  Lei, Han ^a   Sheng, Zhina ^b   Ding, Qian ^b   Chen, Jian ^b   Wei, Xiaohui ^b   Lam, Dominic Man Kit ^c   Xu, Yuhong ^b  

^a NANCHANG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VECTOR; CHOLERA TOXIN B SUBUNIT; GAMMA INTERFERON; HEMAGGLUTININ; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PGSA HEMAGGLUTININ 1 FUSION PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE FUSION; IN VITRO STUDY; INFECTION PREVENTION; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; LACTOCOCCUS LACTIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, VIRAL; CHOLERA TOXIN; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LACTOCOCCUS LACTIS; MICE; ORTHOMYXOVIRIDAE INFECTIONS; TREATMENT OUTCOME;

EID: 79960120764     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00050-11     Document Type: Article

References (37)

1. Aldovini, A., and R. A. Young. 1991. Humoral and cell-mediated immune response to live recombinant BCG-HIV vaccines. Nature 351:479-482.
2. Asahi-Ozaki, Y., et al. 2006. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect. 8:2706-2714. (Pubitemid 44692546)
3. + T cells against Listeria monocytogenes in the murine infection model. Vaccine 26:5304-5314.
4. Bermúdez-Humarán, L. G. 2009. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum. Vaccin. 504:264-267.
5. Bermúdez-Humarán, L. G., G. Corthier, and P. Langella. 2004. Recent advances in the use of Lactococcus lactis as live recombinant vector for the development of new safe mucosal vaccines. Recent Res. Dev. Microbiol. 8:147-160.
6. Carter, N. J., and G. L. Plosker. 2008. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 22:279-292.
7. Chen, M. W., et al. 2008. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 105:13538-13543.
8. Cong, Y., C. T. Weaver, and C. O. Elson. 1997. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J. Immunol. 159:5301-5308.
9. Darji, A., et al. 1997. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91:765-775. (Pubitemid 28007733)
10. Elson, C. O., and W. Ealding. 1985. Genetic control of the murine immune response to cholera toxin. Eur. J. Immunol. 135:930-932.
11. Gilbert, C., K. Robinson, R. W. Le Page, and J. M. Wells. 2000. Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis. Infect. Immun. 68:3251-3260.
12. Horimoto, T., and Y. Kawaoka. 2006. Strategies for developing vaccines against H5N1 influenza A virus. Trends Mol. Med. 12:506-514.
13. Kou, Z., et al. 2009. The survey of H5N1 flu virus in wild birds in 14 provinces of China from 2004 to 2007. PLoS One 4:e6926.
14. Lalor, P. A., et al. 2008. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J. Infect. Dis. 197:1643-1652.
15. Langridge, W., B. Dénes, and I. Fodor. 2010. Cholera toxin B subunit modulation of mucosal vaccines for infectious and autoimmune diseases. Curr. Opin. Invest. Drugs 11:919-928.
16. Lee, J. S., et al. 2006. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibody in mice. J. Virol. 80:4079-4087.
17. Lee, J. S., K. S. Shin, J. G. Pan, and C. J. Kim. 2000. Surface-displayed viral antigen on Salmonella carrier vaccine. Nat. Biotechnol. 18:645-648.
18. Lee, M. H., Y. Roussel, M. Wilks, and S. Tabaqchali. 2001. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 19:3927-3935. (Pubitemid 32566316)
19. Lei, H., Y. Xu, J. Chen, X. Wei, and D. M. Lam. 2010. Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology 407:319-324.
20. Li, K. S., et al. 2004. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430:209-213. (Pubitemid 38902429)
21. Lin, J., et al. 2006. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368:991-997. (Pubitemid 44353667)
22. Medina, M., et al. 2008. Nasal immunization with Lactococcus lactis expressing the pneumococcal protective protein A induces protective immunity in mice. Infect. Immun. 76:2696-2705.
23. Prabakaran, M., et al. 2008. Protective immunity influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 380:412-420.
24. Quigley, B. R., et al. 2010. A foreign protein incorporated on the tip of T3 pili in Lactococcus lactis elicits systemic and mucosal immunity. Infect. Immun. 78:1294-1303.
25. Robinson, K., L. M. Chamberlain, K. M. Schofield, J. M. Wells, and R. W. Le Page. 1997. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat. Biotechnol. 15:653-657.
26. Robinson, K., et al. 2004. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infect. Immun. 72:2753-2761.
27. Saluja, V., et al. 2010. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. AAPS J. 12:109-116.
28. + T cells and antiviral protective immunity. J. Virol. 75:9665-9670.
29. Shen, H., et al. 1998. Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity. Cell 92:535-545. (Pubitemid 28101116)
30. Smith, G. J., et al. 2006. Emergence and predominance of an H5N1 influenza variant in China. Proc. Natl. Acad. Sci. U. S. A. 103:16936-16941.
31. Steitz, J., et al. 2010. Assessment of route of administration and dose escalation for an adenovirus-based influenza A virus (H5N1) vaccine in chickens. Clin. Vaccine Immunol. 17:1467-1472.
32. Van Kampen, K. R., et al. 2005. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23:1029-1036. (Pubitemid 40037652)
33. Wells, J. M., and A. Mercenier. 2008. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat. Rev. Microbiol. 6:349-362.
34. Xin, K. Q., et al. 2003. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 102:223-228.
35. Ye, J., et al. 2010. Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice. Clin. Vaccine Immunol. 17:1363-1370.
36. Zheng, L., et al. 2009. A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect. Dis. 9:17.
37. Zhou, Y., et al. 2008. Electroporation at low voltages enables DNA vaccine to provide protection against a lethal H5N1 avian influenza virus challenge in mice. Intervirology 51:241-246.